STADA to Acquire Biopharma’s Pharmaceutical Prescription and Consumer Health Business to Expand Its Footprint in Ukraine

 STADA to Acquire Biopharma’s Pharmaceutical Prescription and Consumer Health Business to Expand Its Footprint in Ukraine

STADA to Acquire Biopharma’s Pharmaceutical Prescription and Consumer Health Business to Expand Its Footprints in Ukraine

Shots:

  • STADA to acquire Biopharma’s pharmaceutical prescription and consumer health business including local manufacturing operations and ~300 new staff. Biopharma will retain its blood plasma-based business and will focus on its development both in Ukraine and outside Ukraine
  • The acquisition will complement STADA’s European growth strategy and allow STADA to become a major pharma player in Ukraine. The transaction is expected to be close in Dec’2019
  • The acquisition follows STADA’s purchase of six GSK OTC products in August 2019 and its acquisitions of the EMEA distribution rights to Nizoral and controlling stakes in Pymepharco and Bioceuticals in 2018

Click here to­ read full press release/ article | Ref: STADA | Image:  STADA

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post